论文部分内容阅读
宫颈癌是女性最常见的恶性肿瘤之一,其发病率仅次于乳腺癌,其中85%发生在发展中国家,并呈年轻化的趋势[1,2]。中国卫生部统计数据显示,中国每年新增宫颈癌病例超过13万人,死亡人数约为3万人。目前为预防HPV造成的宫颈癌的发生,临床上已使用HPV疫苗来预防该病毒的感染。笔者采用含有抗肿瘤及抗病毒作用成分的保妇康栓治疗HPV感染,对比干扰素,探讨保妇康栓的有效性,为临床研究HPV感染的治疗提供数据支持和实践依据。
Cervical cancer is one of the most common malignant tumors in women. Its incidence is second only to that of breast cancer, with 85% of them occurring in developing countries and showing a younger tendency [1,2]. Statistics from the Chinese Ministry of Health show that there are more than 130,000 new cases of cervical cancer in China every year, with a death toll of about 30,000. At present, in order to prevent the occurrence of cervical cancer caused by HPV, HPV vaccine has been used clinically to prevent the infection of the virus. The author used anti-tumor and anti-virus ingredients of Baofukang suppository treatment of HPV infection, compared with interferon, to explore the effectiveness of Baofukang suppository, for the clinical study of HPV infection treatment to provide data support and practical basis.